Kornimate/medical-research-clean huggingface dataset:
cycling through the menstrual cycle

Conditions: Menstrual Cycle-based Periodized Training; Female Athlete Triad; Menstrual Cycle

Summary: with an increase in number of female athletes in sport events, it is becoming more important to gain insight in female related sports physiology. a main difference between male anf female athletes is the menstrual cycle. during the menstrual cycle, female reproductive hormones fluctuate. these hormones are also of influence on endurance, recovery, muscle strenght and mental state. therefore we hypothesize that training efficiancy, power and motivation to train differ during the menstrual cycle. in case there is a pattern seen during the menstrual cycle, training programs can be individualized taking the menstrual cycle into account leading to more effective training programs.

more and more women are trying to take their menstrual cycle into account when it comes to training effort, planning and performance. this is called menstrual cycle-based periodized training. however, it is still unknown what the exact influence of the different phases of the menstrual cycle is on training and performance. this includes the influence of hormonal fluctuations during the cycle on training capacity, effort load, restorative capacity, motivation to train and perform, daring to take risks and the mental aspects surrounding training and performance. as a result, general advice about cycle-based periodized training cannot be given at this time. it has been described in the literature that professional-level cyclists regularly have menstrual cycle disorders (ie red-s). this has short-term health consequences (less rapid recovery, fatigue) and long-term (osteoporosis, increased risk of cardiovascular disease). at a professional level, this knowledge is slowly penetrating. less is known about the menstrual cycle of amateur athletes and there is also a lack of knowledge about the effects of the menstrual cycle on performance (endurance capacity, heart rate zones, power achieved). to gain more insight into the menstrual cycle, the influence of the cycle on training and performance and the influence of training on the cycle of the sporting woman, the aim of this study is to monitor the menstrual cycle of female cyclists in combination with their subjective and objective training parameters. this allows us to create insight and, if useful, adapt training on an individual basis to the phase of the menstrual cycle. the aim of this research is to investigate how the cyclists' menstrual cycle progresses and whether the cycle has an effect on performance.

Eligibility criteria:
inclusion criteria: * join cycling app member * female cyclist * informed consent period tracking in join exclusion criteria: * none

Keywords: menstrual cycle artificial intelligence cycling female athlete triad female athletes menstrual cycle-based periodized training
bct-ha kit for dehydrated and wrinkled skin

Conditions: Rhytides; Wrinkle

Summary: this study will assess the efficacy of cellular matrixtm bct-ha kit treatment compared to placebo condition on revitalization and skin rejuvenation on the midface. particular attention will be made to the safety aspects, as well as the histological consequences of treatment.


Eligibility criteria:
inclusion criteria: * subjects who are able to give voluntary, written informed consent to participate in this study and from whom consent has been obtained including hippa authorization * healthy men and women, ages 30 - 65 years of age * subjects with fitzpatrick photo skin type i-vi * subjects with moderate to severe nasolabial folds contour deficiencies or other facial wrinkles. degree of nasolabial folds or other facial wrinkles will be determined on the basis of the wrinkles severity rating scale * subjects who agree not to have any other procedures of affecting skin quality (microdermabrasion, peels, acne treatments, toxin, fillers etc.) for the duration of the study * subjects who understand the study and are able to follow study instructions and are willing to attend the required study visits. * subjects who agree to be photographed for research purposes and their identity may not be concealed in these photographs. exclusion criteria: * subjects who have had any kind of aesthetic therapy (peeling, laser, ultrasound, toxins, fillers) in the facial area during the last 6 months * presence of implant in the facial area to treat * contraindications to the use of antiseptics (biseptine, amukine) * subjects who have an active or known skin inflammation or infection within the treatment area. * subjects who have an active or known acute skin allergies * subjects who have a known allergy to hyaluronic acid * subjects who have any other dermatologic conditions including acne, rosacea, eczema, psoriasis, actinic keratosis, severe sun damage, infection, or scars within the treatment area. * subjects of child-bearing potential who are not using an approved method of birth control (oral contraceptives, iud, contraceptive implant, barrier methods with spermicide or abstinence). females of non-childbearing potential are defined as post-menopausal (absence of menstrual bleeding for one year), hysterectomy, or bilateral oophorectomy. * subjects who are pregnant, planning to become pregnant or breastfeeding. a urine pregnancy test will be done to rule out pregnancy. * subjects who have been diagnosed with diabetes * subjects who are immunosuppressed * subjects who are hiv+ / vhb+ / vhc+ * subjects who have had/will have a covid vaccine within 2 weeks of study participation * subjects who have had/will have a dental procedure within 4 weeks of study participation * subjects with a history of severe bee allergy

Keywords: rhytides wrinkles facial aging prp hyaluronic acid
genasense® (oblimersen sodium), fludarabine, and rituximab in subjects with chronic lymphocytic leukemia

Conditions: Chronic Lymphocytic Leukemia

Summary: the treatment combination of rituxan® (rituximab) and fludarabine has previously been reported to produce a high percentage of responses with less toxicity than other combination treatments. however, some leukemia subjects continue to have leukemia despite treatment with these standard anticancer drug therapies, or they may work for only a short period of time. in some subjects, when the leukemia does not respond well to therapy the leukemia cells may be over-producing one or more proteins. one of these proteins is called bcl-2. bcl-2 is a protein that appears to protect cancer cells from being killed and thus lengthens the life of the cancer cells. genasense® (oblimersen sodium) is a compound that blocks production of the bcl-2 protein. by first lowering levels of bcl-2, it is possible that chemotherapy drugs may work more effectively as a cancer treatment. genasense® may also directly kill cll cells. this study will test whether treating subjects with genasense®, fludarabine and rituximab is safe and effective.


Eligibility criteria:
key inclusion criteria: * absolute lymphocyte count of \> 10,000 cells/mm3 or history of alc \>10,000 cell/mm3 * platelets \> 50,000 cells/mm3 * tumor lymphocytes expressing surface cd5, cd19, cd20 and cd23 * creatinine \< 1.5 mg.dl key exclusion criteria: * less than 3 weeks from any prior major surgery or other therapy for cll including radiation therapy, chemotherapy, high-dose steroid therapy, immunotherapy, cytokine, biologic or vaccine therapy. * history of autoimmune hemolytic anemia * prior allogeneic transplant

Keywords: cll leukemia chronic cancer adult lymphocytic genasense g3139 genta bcl-2 antisense oligonucleotide oblimersen
kinesiophobia scale for the upper extremity

Conditions: Shoulder Injuries

Summary: questionnaires/scales used to evaluate kinesiophobia in the literature are limited and are not specific to the upper extremity in existing scales. for this reason, the primary purpose and subject of the study is to develop a multi-factor kinesiophobia scale specific to shoulder problems. the study is an observational research. participants will be interviewed twice in total. all primary and secondary outcomes will be assessed at the first meeting. the second come will be performed within 5-7 days after the first assessment. in the second come, only the new kinesiophobia scale that is intended to be developed will be applied.


Eligibility criteria:
inclusion criteria: * tampa kinesiophobia score \>37 points * presence of traumatological, orthopedic and rheumatological pathology in the upper extremity * mini-mental state examination score \>24 points exclusion criteria: * malignancy, * psychiatric drug use, * use of painkillers during evaluation periods, * those who received physiotherapy before the study (last 6 months), * those whose education level is below secondary school level,

Keywords: kinesiophobia shoulder development of scale
cholera-hospital-based-intervention-for-7-days

Conditions: Cholera; Diarrhea; Stunting

Summary: the cholera hospital based intervention for 7 days (chobi7) randomized controlled trial for transition to scale aimed to: (1) develop and evaluate scalable approaches to integrate the chobi7 intervention into the services provided for hospitalized diarrhea patients at health facilities in bangladesh; and (2) evaluate the ability of the chobi7 intervention to lead to a sustained uptake of the promoted hand washing with soap and water treatment behaviors and significant reductions in diarrheal disease over time.

the findings from the recent randomized controlled trial of the cholera hospital based intervention for 7 days (chobi7) demonstrated that this intervention was effective in significantly reducing symptomatic cholera infections in intervention households, and had significant sustained impacts on hand washing with soap behaviors and improved water quality 12 months post intervention. next steps to transition to scale were: (1) develop and evaluate scalable approaches to integrate the chobi7 intervention into the services provided for hospitalized diarrhea patients at health facilities in bangladesh; and (2) evaluate the ability of the chobi7 intervention to lead to a sustained uptake of the promoted hand washing with soap and water treatment behaviors and significant reductions in diarrheal disease over time.

Eligibility criteria:
inclusion criteria: diarrhea patients will be defined as patients having acute watery diarrhea three or more loose stools over a 24-hour period in the past three days. diarrhea patients admitted to icddrb dhaka hospital or mugda general hospital will be eligible for the trial if: 1. have had 3 or more loose stools over the past 24 hours 2. plan to reside in dhaka for the next 12 months 3. have no basin for running water in their home 4. have a child under five years of age in their household (including themselves) that produced a stool sample at baseline 5. have a working mobile phone in the household. household members of the diarrhea patient will be eligible for the trial if: 1. they have shared the same cooking pot and resided in the same home with the diarrhea patient for the last three days 2. plan to reside in their current household with the diarrhea patient for the next 12 months exclusion criteria: (1) children in foster care will be excluded from all research study activities.

Keywords: handwashing with soap water treatment behavior change water, sanitation and hygiene
drowning incidents treated by the danish sar helicopters

Conditions: Drowning; Drown; Drowning; Anoxia; Drowning, Near; Drowning and Nonfatal Submersion; Drowning or Immersion of Unknown Intent; Drowning and Submersion, Undetermined Intent; Drowning and Submersion While in Natural Water; Drowning and Submersion Due to Sailboat Sinking; Drowning and Submersion Due to Fall Off Ship

Summary: improving oxygenation and ventilation in drowning patients early in the field is critical and may be lifesaving. this may be achieved by helicopter emergency medical services (hems) such as the danish air ambulance, or the royal danish air force's search and rescue (sar) helicopters. the sar operates in all weather conditions and is equipped with a hoist system, able to hoist patients from the sea or small ships without helipads. this study aimed to estimate the incidence of drowning missions attended by the royal danish air force's sar helicopter and describe patient characteristics and prehospital interventions.

the national danish drowning cohort contains data on all fatal and non-fatal drowning patients treated by the emergency medical services. however, data on drowning patients treated by the sar helicopters is reported in a separate system. the population of drowning patients treated by the sar helicopters has never been described, thus contributing to the potential underreporting of the most critically ill drowning patients in denmark. given the rarity of drowning, registry-based studies are needed to provide patient characteristics and evaluate critical care interventions performed on this group of patients. this study aims to identify and describe a national cohort of drowning patients at sea treated by the royal danish air force's sar helicopters from 2014 to 2023.

Eligibility criteria:
inclusion criteria: * patients treated by the danish sar helicopters and * drowning as defined by the who (the process of experiencing respiratory impairment from submersion or immersion in liquid) exclusion criteria: * patients who have not been immersed or submersed. * duplets. * interhospital transfers.

Keywords: drowning danish drowning formula royal danish air force search and rescue (sar) emergency medical service (ems) registry retrospective epidemiology danish prehospital drowning data
predictive factors of long term outcome in mmn

Conditions: MMN

Summary: the cornerstone treatment for multifocal motor neuropathy (mmn), a rare and disabling dysimmune neuropathy, is intravenous immunoglobulin (ivig). the aim of this study is to identify prognostic factors of poor outcome. data were retrospectively collected from mnn patients in three french centers. patients were divided into two groups: a good outcome group and a poor outcome group. demographic, clinical, biological and nerve conduction study features of mmn patients were analyzed. identification of prognostic factors in mmn could help develop personalized treatment.

the cornerstone treatment for multifocal motor neuropathy (mmn), a rare and disabling dysimmune neuropathy, is intravenous immunoglobulin (ivig). however, 10% of patients progress despite treatment. the aim of this study is to identify prognostic factors of poor outcome. data were retrospectively collected from mnn patients in three french centers. patients were divided into two groups: a good outcome group (patients in remission without ivig or with spaced ivig courses), and a poor outcome group (patients dependent on continuous ivig treatment or deteriorating despite ivig). investigators searched predictive factors of long-term outcome in mmn. they studied demographic, clinical, biological and nerve conduction study features of mmn patients.identification of prognostic factors in mmn could help develop personalized treatment by selecting patients eligible for immunosuppressive drugs before ivig dependence or progression.

Eligibility criteria:
inclusion criteria: * diagnosis of mnn following the european federation of neurological societies/peripheral nerve society (efns/pns) guideline criteria 2010 exclusion criteria: * missing data * clinical progression features suggested another inflammatory neuropathy, * immunosuppressive agents for another pathology.

Keywords: predictive factors
predictive model for prognosis of chronic hbv infection mothers

Conditions: Hepatitis B, Chronic

Summary: pregnancy is a complex and coordinated physiological process. pregnancy and the postpartum period are associated with unique changes in the immune system that may impact the natural history of autoimmune diseases and immune-mediated infections. in the postpartum period. alt ﬂares have been reported in 20%-60% of untreated women and were more likely to occur in hepatitis b e antigen (hbeag)-positive patients. it has been postulated that postpartum alt ﬂares may arise to rapid immune restitution against hepatitis b virus (hbv) antigens in the liver, when may be a timing of antiviral treatment. a large number of previous studies have focused on studies on the interruption of mother-to-child transmission in women with chronic hepatitis b(chb), but studies on the prognosis of mothers undergoing pregnancy and delivery are very limited. what are the factors that affect the clearance of hbeag or hbsag? what kind of antiviral treatment protocol should be adopted for mothers with chb? it is not only a problem that needs to be solved urgently in clinical practice, but also can provide some clues for understanding the occurrence and development of hbv infection in women of childbearing age. overall, this study intends to carry out a multi-center two-way cohort study on e antigen-positive chb women in 9 hospitals in shaanxi province. to observe the dynamic changes of virological parameters in these patients, figure out the factors of the serum hbsag loss and hbeag seroconversion, and establish relevant predictive models.


Eligibility criteria:
inclusion criteria: * age 20-45 years old * serum hbsag positive\> 6 months * hbeag positive at delivery * good compliance exclusion criteria: * women who give birth to stillbirth due to various reasons * coinfection with hiv,hcv, syphilis or other sexually transmitted diseases * severe kidney, cardiovascular, lung, nervous system or immune system diseases * who are taking immunotherapy drugs or anti-tumor drugs
a dose ranging study of pf-00868554 in combination with pegasys and copegus in patients with chronic hepatitis c genotype 1 infection

Conditions: Hepatitis C

Summary: the purpose of this study is to further assess the potency of pf-00868554, an hcv polymerase inhibitor, in subjects chronically infected with hcv by evaluating the antiviral activity of pf-00868554 in combination with current standard of care therapy, pegylated interferon-alpha2a (pegasys) and ribavirin (copegus).


Eligibility criteria:
inclusion criteria: * treatment naive (no prior treatment with ifn-a +/- rbv regimens. * subjects who have discontinued ifn-a containing regimens after \<2 weeks of therapy due to tolerability issues are considered treatment naive. * hcv rna \> 100,000 iu/ml at screening. * genotype 1. * a diagnosis of chronic hcv infection for at least 6 months. exclusion criteria: * evidence of acute or chronic infection with hiv or hbv. * exposure within the previous three months to an investigational anti-hcv agent. * evidence of severe or decompensated liver disease. * subjects with liver disease unrelated to hcv infection.
study: effects of a collaborative occupational therapy interactive vaulting

Conditions: Executive Function; Social Interaction; Disability, Developmental

Summary: occupational therapy services will be integrated into an interactive vaulting program which is an equine assisted activity. children with disabilities ages 5-17 will participate. the objectives of this study are to determine the influence of a collaborative occupational therapy interactive vaulting program on the executive function and social participation in children with disabilities.

investment by researchers has been made, however, little research exists that systematically evaluates the effectiveness of occupational therapy (ot) interventions in equine assisted activities, and none have included interactive vaulting. research that has been conducted has supported the use of equines in ot treatment sessions (hippotherapy) in increasing length of time engaged in activities, compared to conventional therapy as well as improvements in postural sway, adaptive behaviors, and participation. in addition, it has been found that children with visual impairments who participated in a 6-week eat program demonstrated clinically significant changes in occupational performance and qualitative themes of peer interaction, taking on challenges and overall satisfaction with the program. the gaps in research warrant investigation into the efficacy of this intervention in the development of executive functioning and social skills in children with disabilities. further research needs to be conducted to determine the effectiveness of occupational therapy in this context. occupational therapy interventions will be integrated into the existing program. group interventions will target the emotional awareness and regulation, social skills, and use cognitive strategies to improve social interactions with peers and adults.

Eligibility criteria:
inclusion criteria children must: * have a documented developmental disability * be eligible only to participate in equine assisted activities. * be ambulatory with or without an assistive device * be able to follow 2-3 step directions * not be aggressive toward animals, peers, or staff exclusion criteria: children who: * do not have a documented developmental disability * are only eligible for equine assisted therapy because of significant physical and/ or medical limitations (i.e.: occupational, physical, or speech therapy). * are non-ambulatory * are unable to follow 2-3 step directions * are aggressive towards animals, peers, or staff * does not have a developmental disorder (i.e.: has only mental health disorder)
development of a patient-reported outcome measure to assess symptoms in patients with primary sclerosing cholangitis (psc)

Conditions: Primary Sclerosing Cholangitis

Summary: the objectives of this qualitative study are to elicit concepts about symptoms that are important to patients with primary sclerosing cholangitis (psc), as well as the key impacts of symptoms on patients' day-to-day functioning.

in step i, concept elicitation one-on-one interviews (via telephone or in person) will be conducted. the aims of the concept elicitation interviews are to: 1. identify the most common symptoms, as well as the most important symptoms, for patients with psc, and 2. assess whether these symptoms impact day-to-day functioning an instrument will be developed based on the symptoms reported and in step ii of the study, the performance of the instrument will be assessed with further interviews.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of psc based on liver biopsy or diagnostic imaging, with diagnosis made at least three months prior to screening * patient report of psc symptoms associated with psc diagnosis * able to speak, read, and understand english * willing and able to provide written informed consent to participate in the research study exclusion criteria: * patients with other causes of liver or biliary disease, including viral hepatitis, alcoholic liver disease, primary biliary cirrhosis, and secondary sclerosing cholangitis * patient with history of liver cirrhosis * patients with history of cholangiocarcinoma * patients who have received a liver transplant * patients currently enrolled in psc clinical trials; and * step ii only: enrolled in or participated in step i of this study (concept elicitation)

Keywords: primary sclerosing cholangitis psc
secondary rupture of aortic aneurysm post evar

Conditions: Aortic Aneurysm

Summary: post-stent rupture of the abdominal aorta is a rare occurrence and with few publications: only 2 multicenter studies and one meta-analysis in 2017 listed this complication as well as a few cases reports this study, the first carried out in france, aims to describe the survival in patients with secondary rupture of the aneurysm despite initial treatment with evar.


Eligibility criteria:
inclusion criteria: * - patient who had a ruptured aortic aneurysm between 01/01/1993 and 07/31/2020) * patients whose aortic aneurysm has been treated with evar exclusion criteria: * no